Hospital
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院
At a glance
Published values only, each read from the record this page is built on. The listings behind them are in the section below.
-
Fudan University hospital rankings A+++ General list, 2023
-
National key clinical specialties 4 at evidence level A or B
-
Published research 17 PubMed records we hold for this hospital (the newest twenty per hospital)
-
Registered studies 25 records we hold for this hospital, as registered
Rankings & accreditation
These listings are published by the bodies that run them, not by this site. Every line carries the year it was published and a link to its source; this is not a paid or promoted listing.
Fudan University hospital rankings
| Item | Rank / tier | Year | Caliber | Source |
|---|---|---|---|---|
| General list | A+++ | 2023 | Tier only; hospitals in the same tier are not ordered against each other | https://rank.cn-healthcare.com/fudan/national-general |
Fudan specialty reputation ranking
| Item | Rank / tier | Year | Caliber | Source |
|---|---|---|---|---|
| Thoracic Surgery 胸外科 | #10 | 2023 | Place in the specialty reputation ranking | https://www.fdygs.com/news2023-1.aspx |
| Medical Oncology 肿瘤学 | #3 | 2023 | Place in the specialty reputation ranking | https://www.fdygs.com/news2023-1.aspx |
National key clinical specialties
| Specialty | Evidence | Source |
|---|---|---|
| Integrated Traditional Chinese and Western Medicine 中西医结合科 | Level B | https://www.shca.org.cn/home/news/content/id/297/pid/25651 |
| Pathology 病理科 | Level B | https://www.shca.org.cn/home/news/content/id/297/pid/25651 |
| Medical Oncology 肿瘤科 | Level B | https://www.shca.org.cn/home/news/content/id/297/pid/25651 |
| Hepatobiliary Surgery 胰腺肿瘤 | Level B | https://www.shca.org.cn/home/news/content/id/297/pid/25651 |
Batch is not published by the source.
4 specialty rows, each carrying its own evidence level.
Each row carries its own evidence level and its own source. Level definitions are on the methodology page.
Values written in Chinese are quoted as published by the source.
Administrative grade
| Item | Rank / tier | Year | Caliber | Source |
|---|---|---|---|---|
| Grade as published Tier 3, class A specialised hospital (re-accredited) 三级甲等专科医院(复评) | Tier 3, class A | 2020-12-24 | An administrative designation, not a ranking; the date is the list's own publication date, not the year the grade was awarded | The source of this record, at the foot of this page |
Conditions treated here
Conditions this site files under the specialties above. It is a record of the listings, not a recommendation.
For international patients
A line appears here only where we hold a record for it. A line that is missing has not been verified - ask us and we will put the question to the hospital.
Hospital details
- Chinese name
- 复旦大学附属肿瘤医院
- English name
- Fudan University Shanghai Cancer Center
- Grade
- Tier 3, class A specialised hospital (re-accredited) 三级甲等专科医院(复评)
- Grade list as published
- 2020-12-24
Values written in Chinese are quoted as published by the source.
The grade list reference is the date or review batch the official list was published under; it is quoted in the source's language.
Also known as
- FUSCC
Evidence for this condition
Selected using official public data sources
-
Colorectal cancer
Published research
- Eggerthella lenta disrupts the gut vascular barrier to drive colorectal cancer liver metastasis. Cell discovery, 2026
- E3 ubiquitin ligase COP1-mediated GSK3β degradation activates β-catenin signaling to facilitate colorectal cancer cell proliferation. Acta biochimica et biophysica Sinica, 2026
3 more published studies
PubMed indexes 5 papers on this condition that name this hospital.
Also ranked: Thoracic Surgery #10, Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Breast cancer
Published research
- Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. Targeted oncology, 2026
- High-Density Type I Collagen Promotes IFN-γ(+) CD8(+) T Cell Exhaustion via SAT1-ASS1-Mediated Glutamine Accumulation and Ferroptosis in Triple-Negative Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026
4 more published studies
PubMed indexes 6 papers on this condition that name this hospital.
Also ranked: Thoracic Surgery #10, Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Lung cancer
Fudan specialty reputation ranking 2023
- Thoracic Surgery #10 https://www.fdygs.com/news2023-1.aspx
Also ranked: Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Liver cancer
National key clinical specialty
- Hepatobiliary Surgery (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
Published research
- The conversion window in hepatocellular carcinoma: When resectability alone is not an indication for surgery. Drug discoveries & therapeutics, 2026
- Combination of programmed death protein-1 inhibitor improves the efficacy of transarterial chemoembolization plus lenvatinib for unresectable intermediate-stage hepatocellular carcinoma: a real-world multi-center retrospective study. European journal of radiology, 2026
PubMed indexes 2 papers on this condition that name this hospital.
Also ranked: Thoracic Surgery #10, Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Stomach cancer
Published research
- Single-cell transcriptomics reveals CD8 + T-cell heterogeneity linked to immunotherapy response in gastric cancer. Biochemical and biophysical research communications, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Thoracic Surgery #10, Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Esophageal cancer
Fudan specialty reputation ranking 2023
- Thoracic Surgery #10 https://www.fdygs.com/news2023-1.aspx
Published research
- ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma. Annals of surgical oncology, 2026
- A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma. Annals of surgical oncology, 2026
1 more published study
PubMed indexes 3 papers on this condition that name this hospital.
Also ranked: Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Pancreatic cancer
Fudan specialty reputation ranking 2023
- Medical Oncology #3 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
- Hepatobiliary Surgery (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
Also ranked: Thoracic Surgery #10, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Liver transplantation
National key clinical specialty
- Hepatobiliary Surgery (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
Also ranked: Thoracic Surgery #10, Medical Oncology #3, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Bone and soft tissue sarcoma
Fudan specialty reputation ranking 2023
- Medical Oncology #3 https://www.fdygs.com/news2023-1.aspx
National key clinical specialty
- Medical Oncology (level B) https://www.shca.org.cn/home/news/content/id/297/pid/25651
Also ranked: Thoracic Surgery #10, Nuclear Medicine 核医学 nominated in the Fudan list.
Other hospitals in Shanghai
Source & evidence
- Source URL
- https://rank.cn-healthcare.com/fudan/national-general
- Source scheme
- https
- Source type
- Third-party compilation
- Evidence level
- B - hospital self-statement or authoritative media
- Retrieved on
- 2026-09-24